Sanofi says MS treatment reduced relapse rate

PARIS (Reuters) – Sanofi said on Friday that a trial of its multiple-sclerosis treatment teriflunomide found that a daily dose of the drug reduced the annualized rate of relapse by 36 percent compared with a placebo. Teriflunomide, marketed as Aubagio, is one of the two multiple sclerosis drugs Sanofi has in late-stage development and one of several oral MS treatments being developed by major drug companies. (Reporting By Christian Plumb)